SGLT2阻害薬とスルホニル尿素薬の2型糖尿病とNAFLDの比較

基本情報

NCT ID

NCT02649465

ステータス

完了

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

40

治験依頼者名

Kanazawa University

概要

The clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to the reduction in liver fibrosis scores during the histological course of NAFLD development. These findings led us to hypothesize that glycemic control and insulin ameliorate or protect against the histological progression of liver fibrosis in patients with NAFLD. In the present study, we investigated the efficacy of SGLT2 inhibitor tofogliflozin and sulfonylurea glimepiride, which lower glucose levels similarly with reduction and elevation in circulating insulin levels, respectively, in NAFLD patients with type 2 diabetes for 48 weeks by examining liver histology, as well as hepatic enzymes, metabolic markers, and hepatic gene expression profiles.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)